CAR-ITNK Cell Therapy

N/A

Report date: 2022/03/22 16:51:59

Base Information

Drug NameCAR-ITNK Cell Therapy
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Induced-T cell-like NK cell therapy
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsNot applicable
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanfang Hospital Of Southern Medical University
China Registration ClassN/A

Develop Information

Active CompaniesSouthern Hospital Of Southern Medical University
Inactive CompaniesNanfang Hospital Of Southern Medical University
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A